Ionis Pharmaceuticals, Inc.
IONS
Κατάταξη σε μετοχές
#2555
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Τιμή μετοχής
$45.20
Κεφαλαιοποίηση
$7.51B
Αλλαγή (1 ημέρα)
1.85%
Αλλαγή (1 έτος)
-38.55%
Χώρα
US
Εμπόριο Ionis Pharmaceuticals, Inc. (IONS)
Κατηγορία
Healthcare
Κέρδη για την Ionis Pharmaceuticals, Inc. (IONS)
Κέρδη τον Jun 2026 TTM: $-562.09M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Ionis Pharmaceuticals, Inc., τα τρέχοντα κέρδη της εταιρείας είναι $-562.09M. Το 2023, η εταιρεία παρουσίασε κέρδη $-333.97M, μείωση σε σύγκριση με των κερδών του 2022 που ήταν $-257.99M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Ionis Pharmaceuticals, Inc. από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-562.09M | 22.17% |
| 2024 | $-460.07M | 37.76% |
| 2023 | $-333.97M | 29.45% |
| 2022 | $-257.99M | 785.09% |
| 2021 | $-29.15M | -78.34% |
| 2020 | $-134.55M | -139.72% |
| 2019 | $338.77M | -544.83% |
| 2018 | $-76.16M | 354.31% |
| 2017 | $-16.76M | -70.83% |
| 2016 | $-57.47M | -34.63% |
| 2015 | $-87.91M | 61.62% |
| 2014 | $-54.39M | -18.28% |
| 2013 | $-66.56M | -10.76% |
| 2012 | $-74.59M | -12.03% |
| 2011 | $-84.79M | 38.64% |
| 2010 | $-61.16M | 92.54% |
| 2009 | $-31.77M | 118.78% |
| 2008 | $-14.52M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | -1,038.45% |
US
|
|
| $-3.09B | 449.21% |
US
|
|
| $-4.02B | 614.52% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -447.04% |
NL
|
